Melanoma

Unresectable Stage III-IV

Any Line

1st Line

BRAF +

V600 Wildtype

Melanoma

MEL0023
Phase III
IMO-2125 + Ipiilimumab vs Ipiilimumab Alone in Anti-PD-1 Refractory Melanoma

PI: Reddy
Idera Pharmaceuticals

Requires Injectable Lesions

MEL0022
Phase III
ECDG-ACRIN-EA6141
Phase II/III Nivolumab & Ipiilimumab +/- Sargramostim in Unresectable Stage III/IV Melanoma

PI: Reddy
ECDG-ACRIN

METS0002
Phase III
Intratumoral SD-101 +Pembrolizumab in Metastatic Melanoma or Recurrent /Metastatic HNSCC

PI: Reddy
Dyanavx Technologies Corporation

MEL0019
Phase III
PDR001+ Dabrafenib+ Trametinib vs Placebo+ Dabrafenib+ Trametinib in BRAF V600 Mutant Melanoma

PI: Reddy
Novartis

MEL0022
Phase III
Cobimetinib+ Atezolizumab vs Pembrolizumab in Previously Un-Treated BRAFV600 Wild-Type Melanoma

PI: Reddy
F. Hoffmann-La Roche

KEY

Pending

Open for Enrollment

Observational Study

Optional Path

Link

Trial Posting

Extension Study

Immunotherapy

Enrollment on Hold